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1. INTRODUCTION {#mgg3377-sec-0005}
===============

Hereditary hemorrhagic telangiectasia (HHT) is caused by mutations in TGFβ/BMP9 pathway genes, most commonly *ENG* (OMIM 131195) or *ACVRL1 (ALK1*, OMIM 601284). HHT is characterized by vascular malformations (VM) ranging from small skin and mucosal telangiectases to arteriovenous malformations (AVM) in lung, liver, and brain, which can lead to severe complications including intracranial hemorrhage (ICH) from ruptured brain VM. The clinical heterogeneity of HHT suggests a potential role for genetic modifier effects. Identification and validation of such modifiers could inform disease prognosis and guide clinical management of HHT patients and provide potentially useful stratifier biomarkers for clinical trials. A few such genetic associations with HHT disease features have been reported. Common variants in two loci that modify phenotype severity in *Tgfb* knockout mice (TGFβ modifier loci) have been associated with lung AVM in HHT families (Benzinou et al., [2012](#mgg3377-bib-0004){ref-type="ref"}; Kawasaki et al., [2014](#mgg3377-bib-0007){ref-type="ref"}). We previously showed that the *ACVRL1* c.314‐35A\>G polymorphism, associated with sporadic brain AVM (Pawlikowska et al., [2005](#mgg3377-bib-0017){ref-type="ref"}; Simon et al., [2006](#mgg3377-bib-0019){ref-type="ref"}), is also associated with VM in HHT, but only among patients with *ENG* mutations (Pawlikowska et al., [2015](#mgg3377-bib-0015){ref-type="ref"}). Common variants in other candidate genes have previously been reported to be associated with sporadic BAVM (Kim et al., [2009](#mgg3377-bib-0009){ref-type="ref"}; Mikhak et al., [2011](#mgg3377-bib-0013){ref-type="ref"}; Pawlikowska et al., [2005](#mgg3377-bib-0017){ref-type="ref"}; Su et al., [2010](#mgg3377-bib-0020){ref-type="ref"}) or with sporadic BAVM ICH (Achrol et al., [2006](#mgg3377-bib-0002){ref-type="ref"}, [2007](#mgg3377-bib-0001){ref-type="ref"}; Hysi et al., [2007](#mgg3377-bib-0006){ref-type="ref"}; Pawlikowska et al., [2004](#mgg3377-bib-0018){ref-type="ref"}, [2006](#mgg3377-bib-0016){ref-type="ref"}; Weinsheimer et al., [2009](#mgg3377-bib-0021){ref-type="ref"}). We investigated whether the four TGFβ modifier locus variants previously reported in HHT lung AVM and seven variants from sporadic AVM studies are associated with organ VM and with brain VM ICH in a large cohort of Caucasian HHT patients enrolled by the Brain Vascular Malformation Consortium (BVMC) (Akers et al., [2013](#mgg3377-bib-0003){ref-type="ref"}).

2. MATERIALS AND METHODS {#mgg3377-sec-0006}
========================

2.1. Ethical compliance {#mgg3377-sec-0007}
-----------------------

The study protocol was approved by the institutional review board at each recruiting center. All patients provided written informed consent for genetic studies and a blood or saliva sample for DNA extraction.

2.2. Cohort {#mgg3377-sec-0008}
-----------

The study includes 752 Caucasian HHT patients enrolled by the BVMC at multiple recruiting centers in the US, Canada, and the Netherlands between 2010 and 2015. Cohort recruitment has been previously described (Akers et al., [2013](#mgg3377-bib-0003){ref-type="ref"}; Pawlikowska et al., [2015](#mgg3377-bib-0015){ref-type="ref"}). Patients were screened for organ VM and other clinical features according to standard clinical practice and International HHT Guidelines (Faughnan et al., [2011](#mgg3377-bib-0005){ref-type="ref"}), including: comprehensive history, physical, routine blood tests, and clinical screening for recurrent spontaneous epistaxis and HHT‐related gastrointestinal bleeding. All patients were screened for pulmonary AVM by contrast echocardiography or by chest CT. All patients were screened for brain VM by magnetic resonance imaging. If screening was positive for pulmonary AVM or brain VM (Krings et al., [2015](#mgg3377-bib-0010){ref-type="ref"}), patients underwent further diagnostic imaging and treatment, where appropriate. For liver VM, all patients underwent clinical screening (chronic right upper quadrant pain, portal hypertension, high‐output heart failure, liver bruit on examination, abnormal liver function tests) as well as echocardiography for high‐output cardiopathy. If screening was positive, then diagnostic liver imaging was performed (ultrasound Doppler, contrast CT or contrast MRI) and therapy recommended where appropriate. The BVMC HHT cohort targets 25% brain VM‐positive patients; other characteristics are similar to other cohorts (Letteboer et al., [2006](#mgg3377-bib-0012){ref-type="ref"}; Nishida et al., [2012](#mgg3377-bib-0014){ref-type="ref"}). Brain VM ICH included any ICH during HHT disease course (prior to enrollment or during follow‐up, including after brain VM treatment). For lung AVM, we also defined a severe subphenotype as: diffuse lung AVM and/or feeding artery diameter of largest lung AVM ≥5 mm and/or presence of any of the following complications: ischemic stroke, brain abscess, massive hemoptysis, spontaneous hemothorax.

2.3. Genotyping {#mgg3377-sec-0009}
---------------

DNA was extracted at the NINDS Repository at Coriell Institute (<http://ccr.coriell.org/Sections/Collections/NINDS>), or at UCSF (saliva). We genotyped 11 candidate variants including seven variants from sporadic BAVM studies (*APOE* ε2 haplotype comprising rs7412 and rs429358 (Achrol et al., [2007](#mgg3377-bib-0001){ref-type="ref"}; Pawlikowska et al., [2006](#mgg3377-bib-0016){ref-type="ref"}), *ANGPTL4* rs11672433 (Mikhak et al., [2011](#mgg3377-bib-0013){ref-type="ref"}), *EPHB4* rs314308 (Weinsheimer et al., [2009](#mgg3377-bib-0021){ref-type="ref"}), *IL6*‐174G\>C rs1800795 (Kim et al., [2008](#mgg3377-bib-0008){ref-type="ref"}; Pawlikowska et al., [2004](#mgg3377-bib-0018){ref-type="ref"}), *IL1B*‐31T\>C rs1143627 (Kim et al., [2009](#mgg3377-bib-0009){ref-type="ref"}), *ITGB8* rs10486391 (Su et al., [2010](#mgg3377-bib-0020){ref-type="ref"}), *TNFA*‐238G\>A rs361525 (Achrol et al., [2006](#mgg3377-bib-0002){ref-type="ref"}, [2007](#mgg3377-bib-0001){ref-type="ref"})), and four variants in TGFβ modifier loci (*PTPN14* rs2936018, *USH2A* rs700024 (Benzinou et al., [2012](#mgg3377-bib-0004){ref-type="ref"}), *ADAM17* rs12474540 and rs10495565 (Kawasaki et al., [2014](#mgg3377-bib-0007){ref-type="ref"})) using commercially available Taqman assays according to manufacturer\'s instructions (Applied Biosystems, Foster City, CA). Genotypes were scored by investigators blinded to phenotype. All genotype call rates were \>95%. All variants were consistent with Hardy--Weinberg equilibrium (*p* \> .05).

2.4. Statistical analysis {#mgg3377-sec-0010}
-------------------------

Genotypes were collapsed for analysis into risk genotype carriers versus noncarriers according to published associations with sporadic BAVM (Achrol et al., [2006](#mgg3377-bib-0002){ref-type="ref"}, [2007](#mgg3377-bib-0001){ref-type="ref"}; Hysi et al., [2007](#mgg3377-bib-0006){ref-type="ref"}; Kim et al., [2009](#mgg3377-bib-0009){ref-type="ref"}; Mikhak et al., [2011](#mgg3377-bib-0013){ref-type="ref"}; Pawlikowska et al., [2004](#mgg3377-bib-0018){ref-type="ref"}, [2005](#mgg3377-bib-0017){ref-type="ref"}, [2006](#mgg3377-bib-0016){ref-type="ref"}; Su et al., [2010](#mgg3377-bib-0020){ref-type="ref"}; Weinsheimer et al., [2009](#mgg3377-bib-0021){ref-type="ref"}). For the four TGFβ modifier variants, the published analysis (Benzinou et al., [2012](#mgg3377-bib-0004){ref-type="ref"}; Kawasaki et al., [2014](#mgg3377-bib-0007){ref-type="ref"}) was for familial transmission, which we cannot perform in our nonfamilial cohort, so we used an additive model for the minor (risk) allele, as this is the most general genetic model for a case--control analysis with the fewest additional assumptions. Association of genotype with presence of Any VM (pulmonary, liver or brain), pulmonary AVM, liver VM, brain VM, and ICH from brain VM was evaluated by multivariable logistic regression adjusted for age at last follow‐up, gender and family clustering. The same direction of effect (risk genotype) as previously published was required. The statistical significance threshold was adjusted for 11 variants tested and set at *p* = .0045. We also performed secondary analyses stratified by HHT mutation (*ENG* or *ACVRL1*) for all phenotypes except ICH (where the N of BAVM patients with known HHT mutations was too small to accommodate multivariate analyses for nine variants), and of the severe lung AVM phenotype (to evaluate the effect of a more stringent phenotype definition). One variant‐phenotype analysis could not be evaluated with multivariable logistic regression due to perfect prediction; we instead provide results from univariable exact logistic regression.

3. RESULTS {#mgg3377-sec-0011}
==========

Table [1](#mgg3377-tbl-0001){ref-type="table"} shows demographic and clinical characteristics of the study cohort. Among 752 Caucasian HHT patients, 52% had pulmonary AVM, 20% had liver VM and 21% had brain VM. 20% (30/153) of brain VM cases had ICH (prior to enrollment or during follow‐up).

###### 

Demographic characteristics and HHT phenotypes of study cohort

  Characteristic                 All Subjects    *ENG* mutation   *ACVRL1* mutation   *p*
  ------------------------------ --------------- ---------------- ------------------- --------
  Female sex                     437/752 (58%)   143/240 (60%)    109/200 (55%)       .289
  Age at last follow‐up (year)   47.4 ± 19.6     46.1 ± 19.0      49.0 ± 20.2         .121
  HHT mutation:                                                                       n/a
  *ENG*                          240/455 (53%)   240/240 (100%)   n/a                 
  *ACVRL1*                       200/455 (44%)   n/a              200/200 (100%)      
  *SMAD4*                        15/455 (3%)     n/a              n/a                 
  Any VM                         526/728 (72%)   202/238 (85%)    101/194 (52%)       \<.001
  Lung AVM                       378/730 (52%)   170/235 (72%)    37/195 (19%)        \<.001
  Liver VM                       144/717 (20%)   24/230 (10%)     56/196 (29%)        \<.001
  Brain VM                       156/752 (21%)   78/240 (33%)     22/200 (11%)        \<.001
  ICH from brain VM              30/153 (20%)    14/78 (18%)      5/22 (23%)          .759

Values are no. observed with the specified characteristic over the total no. of nonmissing observations or mean ± standard deviation.

*p*, comparison of *ACVRL1* and *ENG* subjects using Fisher\'s exact test or a two‐sample *t*‐test.

AVM, arteriovenous malformation; ICH, intracerebral hemorrhage; VM, vascular malformation.
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None of the 11 variants was significantly associated with VM in any organ or with ICH (Table [2](#mgg3377-tbl-0002){ref-type="table"}). We did not replicate the previously reported associations of four TGFB modifier variants (Benzinou et al., [2012](#mgg3377-bib-0004){ref-type="ref"}; Kawasaki et al., [2014](#mgg3377-bib-0007){ref-type="ref"}) with HHT lung AVM. There was a trend toward association of one of these variants, *USH2A* rs700024, with ICH from brain VM (OR = 2.77, 95% CI = 1.13--6.80, *p* = .026).

###### 

Association of candidate variant genotype with HHT phenotypes

  Phenotype                         Polymorphism (risk genotypes)     *n*    OR          95% CI      *p*
  --------------------------------- --------------------------------- ------ ----------- ----------- ------
  Any VM                            APOE ε2                           713    0.83        0.52‐1.34   .452
  ANGPTL4 rs11672433 (AA or AG)     708                               0.99   0.66‐1.49   .977        
  EPHB4 rs314308 (AA or AG)         719                               0.76   0.53‐1.08   .124        
  IL1B‐31T\>C, rs1143627 CC)        723                               0.73   0.44‐1.21   .222        
  IL6‐174G\>C rs1800795 (GG)        714                               0.87   0.61‐1.24   .443        
  ITGB8 rs10486391 (AA)             725                               0.83   0.58‐1.19   .311        
  TNF‐238G\>A rs361525 (AA or AG)   722                               0.56   0.32‐1.00   .048        
  ADAM17 rs10495565                 726                               1.04   0.81‐1.33   .775        
  ADAM17 rs12474540                 724                               1.01   0.80‐1.28   .942        
  PTPN14 rs2936018                  717                               0.96   0.71‐1.29   .784        
  USH2A rs700024                    708                               1.12   0.72‐1.76   .613        
  Brain VM                          APOE ε2                           737    0.84        0.50‐1.40   .494
                                    ANGPTL4 rs11672433 (AA or AG)     732    0.78        0.50‐1.20   .256
                                    EPHB4 rs314308 (AA or AG)         743    1.28        0.89‐1.84   .181
                                    IL1B‐31T\>C, rs1143627 CC)        746    1.00        0.57‐1.78   .988
                                    IL6‐174G\>C rs1800795 (GG)        738    0.54        0.36‐0.83   .005
                                    ITGB8 rs10486391 (AA)             749    0.92        0.63‐1.37   .696
                                    TNF‐238G\>A rs361525 (AA or AG)   746    1.01        0.59‐1.74   .959
                                    ADAM17 rs10495565                 750    0.85        0.65‐1.10   .213
                                    ADAM17 rs12474540                 748    0.79        0.61‐1.03   .085
                                    PTPN14 rs2936018                  741    1.05        0.77‐1.44   .749
                                    USH2A rs700024                    732    1.04        0.69‐1.55   .868
  ICH from brain VM                 APOE ε2                           152    0.47        0.10‐2.35   .361
                                    ANGPTL4 rs11672433 (AA or AG)     151    1.89        0.78‐4.59   .158
                                    EPHB4 rs314308 (AA or AG)         153    1.85        0.69‐4.96   .222
                                    IL1B‐31T\>C, rs1143627 CC)        152    1.22        0.37‐4.04   .750
                                    IL6‐174G\>C rs1800795 (GG)        151    0.46        0.15‐1.44   .185
                                    ITGB8 rs10486391 (AA)             152    0.82        0.35‐1.96   .664
                                    TNF‐238G\>A rs361525 (AA or AG)   151    0.93        0.24‐3.54   .915
                                    ADAM17 rs10495565                 151    0.71        0.41‐1.21   .208
                                    ADAM17 rs12474540                 153    0.70        0.42‐1.17   .171
                                    PTPN14 rs2936018                  153    0.89        0.41‐1.93   .770
                                    USH2A rs700024                    147    2.77        1.13‐6.80   .026
  Liver VM                          APOE ε2                           702    0.95        0.53‐1.73   .876
                                    ANGPTL4 rs11672433 (AA or AG)     697    1.26        0.81‐1.96   .300
                                    EPHB4 rs314308 (AA or AG)         708    1.19        0.79‐1.79   .404
                                    IL1B‐31T\>C, rs1143627 (CC)       712    0.40        0.19‐0.86   .019
                                    IL6‐174G\>C rs1800795 (GG)        704    1.03        0.68‐1.56   .884
                                    ITGB8 rs10486391 (AA)             714    0.77        0.52‐1.15   .202
                                    TNF‐238G\>A rs361525 (AA or AG)   711    0.78        0.41‐1.48   .445
                                    ADAM17 rs10495565                 715    1.31        0.98‐1.77   .071
                                    ADAM17 rs12474540                 714    1.42        1.08‐1.87   .013
                                    PTPN14 rs2936018                  706    1.17        0.82‐1.67   .375
                                    USH2A rs700024                    698    1.20        0.77‐1.85   .418
  Lung AVM                          APOE ε2                           715    0.91        0.58‐1.43   .691
                                    ANGPTL4 rs11672433 (AA or AG)     710    0.88        0.62‐1.25   .471
                                    EPHB4 rs314308 (AA or AG)         721    0.78        0.57‐1.07   .120
                                    IL1B‐31T\>C, rs1143627 CC)        724    0.98        0.61‐1.57   .938
                                    IL6‐174G\>C rs1800795 (GG)        716    1.10        0.80‐1.51   .555
                                    ITGB8 rs10486391 (AA)             727    0.70        0.52‐0.96   .027
                                    TNF‐238G\>A rs361525 (AA or AG)   724    0.54        0.33‐0.89   .015
                                    ADAM17 rs10495565                 728    0.98        0.79‐1.22   .879
                                    ADAM17 rs12474540                 726    0.92        0.75‐1.14   .462
                                    PTPN14 rs2936018                  719    1.00        0.77‐1.31   .994
                                    USH2A rs700024                    710    1.03        0.72‐1.46   .892

*p*, multivariable regression adjusted for gender, age at last follow‐up and family clustering.

AVM, arteriovenous malformation; ICH, intracerebral hemorrhage; VM, vascular malformation.
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In secondary analysis, we detected no statistically significant associations between the severe lung AVM subphenotype (100 out of 664 patients (15%) with data available) and the four TGFB modifier loci SNPs (ORs between 0.87 and 0.99, all *p* \> .33). In analysis stratified by *ENG* or *ACVRL1* HHT mutation, among *ENG* mutation carriers only, liver VM were associated with *ADAM17* rs12474540 (OR = 2.82, 95% CI = 1.37--4.30, *p* = .002, Table [S1](#mgg3377-sup-0001){ref-type="supplementary-material"}). There was also a trend toward association of liver VM with *ADAM17* rs10495565 (OR = 2.28, 95% CI = 1.23--4.20, *p* = .009), and with *PTPN14* rs2936018 (OR = 2.82, 95% CI = 1.31--6.08), *p* = .008) (Table [S1](#mgg3377-sup-0001){ref-type="supplementary-material"}).

4. DISCUSSION {#mgg3377-sec-0012}
=============

We did not replicate the previously reported associations between four TGFB modifier loci variants with HHT lung AVM (Benzinou et al., [2012](#mgg3377-bib-0004){ref-type="ref"}; Kawasaki et al., [2014](#mgg3377-bib-0007){ref-type="ref"}) in the overall BVMC cohort. In analysis stratified by HHT gene, among *ENG* mutation carriers only, there was a significant association of one of the four variants, *ADAM17* rs12474540, and a trend toward association of two other TGFB modifier SNPs with liver (but not lung) VM. There was a trend in the same direction in the overall cohort. The lung AVM associations originally reported were also stronger among *ENG* mutation carriers (Kawasaki et al., [2014](#mgg3377-bib-0007){ref-type="ref"}). There was also a trend toward association of another of these variants, *USH2A* rs700024, with ICH from brain VM. These findings may indicate that the TGFB modifier loci variants are associated with multiple HHT phenotypes, but a larger cohort will be required to confirm this. It is not clear why we do not detect a lung AVM association in our cohort, and do not replicate the original finding (Kawasaki et al., [2014](#mgg3377-bib-0007){ref-type="ref"}). To check for a possible effect of different lung AVM ascertainment on the genetic association results, we defined a severe lung AVM phenotype closer to the lung AVM phenotype definition used in the cohort studied in the original report (Letteboer et al., [2015](#mgg3377-bib-0011){ref-type="ref"}; Pawlikowska et al., [2015](#mgg3377-bib-0015){ref-type="ref"}), but did not detect statistically significant associations with any of the 4 TGFB modifier variants. The disparity in genetic association results may also be influenced by methodological differences: the published analysis of lung AVM was performed in families, testing for transmission of risk alleles; we performed a case--control association analysis in a large cohort of mostly unrelated subjects. Another difference between our cohorts was that the BVMC targeted enrollment of 25% brain VM positive patients, resulting in cohort with 21% brain VM positive patients. This proportion is within the upper end of the range of prevalence of brain VM positive patients reported by other cohorts (5%--23% (Akers et al., [2013](#mgg3377-bib-0003){ref-type="ref"})), so we do not expect it to significantly influence the results of our association analysis, however it does represent a divergence from completely unbiased enrollment. Finally, our cohort was North American Caucasians, the original findings were in Dutch and French Caucasians (Benzinou et al., [2012](#mgg3377-bib-0004){ref-type="ref"}; Kawasaki et al., [2014](#mgg3377-bib-0007){ref-type="ref"}). It is possible for population stratification even among/within Caucasian cohorts to influence genetic association results.

We did not detect significant associations between any of the 7 variants previously reported in sporadic BAVM or ICH with HHT brain VM or ICH. Possible explanations include different genetic influences on sporadic and HHT brain AVM, that the original findings (from small cohorts and unreplicated) were false positives, and a false negative, due to lack of power to detect small effects in our cohort. In the case of *ACVRL1* c.314‐35A\>G, the sporadic brain AVM‐associated variant that we found to also be associated with VM in HHT (Pawlikowska et al., [2015](#mgg3377-bib-0015){ref-type="ref"}), the original finding had been replicated in multiple sporadic brain AVM cohorts, and the variant was in an HHT gene. The BVMC cohort of 752 subjects is substantial for a rare disease such as HHT, but may not be sufficient to detect associations of small effect size. We did observe several associations with the same direction of effect as in previous studies; a larger cohort is required to validate these associations. The BVMC is recruiting a second cohort of 800 HHT patients.

Our findings suggest the effects of genetic modifier variants are complex, but given the functional data from animal and in vitro models for the involvement of ADAM17 and PTPN14 in HHT biology (Benzinou et al., [2012](#mgg3377-bib-0004){ref-type="ref"}; Kawasaki et al., [2014](#mgg3377-bib-0007){ref-type="ref"}), it is of interest to revisit these in larger cohorts. Identification and validation of genetic modifiers could inform prognosis and guide clinical management of HHT patients and provide potentially useful stratifier biomarkers for clinical trials.
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